Loading...

BriaCell Therapeutics

TSXV:BCT
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BCT
TSXV
CA$17M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, develops personalized treatments for cancer. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • BriaCell Therapeutics has significant price volatility in the past 3 months.
BCT Share Price and Events
7 Day Returns
0%
TSXV:BCT
-0.5%
CA Biotechs
-0.2%
CA Market
1 Year Returns
-15%
TSXV:BCT
-15.4%
CA Biotechs
-1.9%
CA Market
BCT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BriaCell Therapeutics (BCT) 0% -5.6% -10.5% -15% -54.1% -
CA Biotechs -0.5% -0.4% 0.5% -15.4% -16.3% 12.3%
CA Market -0.2% -1.6% 2.1% -1.9% 13.3% 4.3%
1 Year Return vs Industry and Market
  • BCT underperformed the Market in Canada which returned -1.9% over the past year.
Price Volatility
BCT
Industry
5yr Volatility vs Market

Value

 Is BriaCell Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether BriaCell Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BriaCell Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BriaCell Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is CA$0.085.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BriaCell Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BriaCell Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSXV:BCT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in CAD CA$-0.04
TSXV:BCT Share Price ** TSXV (2019-05-17) in CAD CA$0.09
North America Biotechs Industry PE Ratio Median Figure of 36 Publicly-Listed Biotechs Companies 20.29x
Canada Market PE Ratio Median Figure of 545 Publicly-Listed Companies 14.85x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BriaCell Therapeutics.

TSXV:BCT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:BCT Share Price ÷ EPS (both in CAD)

= 0.09 ÷ -0.04

-2.02x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BriaCell Therapeutics is loss making, we can't compare its value to the North America Biotechs industry average.
  • BriaCell Therapeutics is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does BriaCell Therapeutics's expected growth come at a high price?
Raw Data
TSXV:BCT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.02x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.25x
Canada Market PEG Ratio Median Figure of 252 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BriaCell Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BriaCell Therapeutics's assets?
Raw Data
TSXV:BCT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in CAD CA$0.00
TSXV:BCT Share Price * TSXV (2019-05-17) in CAD CA$0.09
Canada Biotechs Industry PB Ratio Median Figure of 36 Publicly-Listed Biotechs Companies 4.54x
Canada Market PB Ratio Median Figure of 2,407 Publicly-Listed Companies 1.41x
TSXV:BCT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:BCT Share Price ÷ Book Value per Share (both in CAD)

= 0.09 ÷ 0.00

-17.51x

* Primary Listing of BriaCell Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BriaCell Therapeutics has negative assets, we can't compare the value of its assets to the CA Biotechs industry average.

Next steps:

  1. Take a look at our analysis of BCT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through BriaCell Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess BriaCell Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BriaCell Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BriaCell Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BriaCell Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
20.5%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BriaCell Therapeutics expected to grow at an attractive rate?
  • Unable to compare BriaCell Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare BriaCell Therapeutics's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare BriaCell Therapeutics's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSXV:BCT Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 20.5%
Canada Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 37.2%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.5%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSXV:BCT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSXV:BCT Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-01-31 -5 -6
2018-10-31 -5 -6
2018-07-31 -5 -5
2018-04-30 -4 -4
2018-01-31 -3 -4
2017-10-31 -3 -3
2017-07-31 -2 -3
2017-04-30 -2 -2
2017-01-31 -2 -2
2016-10-31 -2 -2
2016-07-31 -2 -2
2016-04-30 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if BriaCell Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if BriaCell Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSXV:BCT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from BriaCell Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:BCT Past Financials Data
Date (Data in CAD Millions) EPS *
2019-01-31 -0.04
2018-10-31 -0.04
2018-07-31 -0.04
2018-04-30 -0.04
2018-01-31 -0.04
2017-10-31 -0.03
2017-07-31 -0.03
2017-04-30 -0.02
2017-01-31 -0.02
2016-10-31 -0.03
2016-07-31 -0.03
2016-04-30 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BriaCell Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of BCT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. BriaCell Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. BriaCell Therapeutics's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess BriaCell Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BriaCell Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BriaCell Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BriaCell Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BriaCell Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BriaCell Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BriaCell Therapeutics's 1-year growth to the North America Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BriaCell Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BriaCell Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:BCT Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 -6.43 2.05 4.37
2018-10-31 -5.82 2.05 3.57
2018-07-31 -5.41 1.93 3.04
2018-04-30 -4.46 1.49 2.73
2018-01-31 -3.98 1.13 2.84
2017-10-31 -3.42 1.13 2.30
2017-07-31 -3.22 1.12 2.09
2017-04-30 -2.42 0.41 1.98
2017-01-31 -1.67 0.68 0.88
2016-10-31 -2.25 1.30 0.91
2016-07-31 -2.21 1.34 0.84
2016-04-30 -2.20 1.92 0.34
2016-01-31 -2.24 1.69 0.69
2015-10-31 -3.83 1.62 0.52
2015-07-31 -3.49 1.47 0.33
2014-07-31 0.00 0.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BriaCell Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if BriaCell Therapeutics has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BriaCell Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess BriaCell Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BriaCell Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BriaCell Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BriaCell Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BriaCell Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • BriaCell Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BriaCell Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BriaCell Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BriaCell Therapeutics Company Filings, last reported 3 months ago.

TSXV:BCT Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 -0.79 0.65 0.54
2018-10-31 0.47 1.08 1.14
2018-07-31 1.23 1.46 2.28
2018-04-30 3.02 1.26 4.34
2018-01-31 0.58 0.00 0.59
2017-10-31 1.27 0.00 1.29
2017-07-31 0.94 0.00 2.01
2017-04-30 2.15 0.00 2.15
2017-01-31 1.78 0.00 1.76
2016-10-31 2.16 0.00 2.18
2016-07-31 1.03 0.00 1.07
2016-04-30 1.43 0.00 1.49
2016-01-31 0.73 0.00 0.79
2015-10-31 1.14 0.00 1.18
2015-07-31 1.51 0.00 1.57
2014-07-31 0.00 0.00 0.03
  • BriaCell Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if BriaCell Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BriaCell Therapeutics has less than a year of cash runway based on current free cash flow.
  • BriaCell Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 48.1% each year.
X
Financial health checks
We assess BriaCell Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BriaCell Therapeutics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BriaCell Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BriaCell Therapeutics dividends.
If you bought CA$2,000 of BriaCell Therapeutics shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BriaCell Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BriaCell Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSXV:BCT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
Canada Market Average Dividend Yield Market Cap Weighted Average of 332 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BriaCell Therapeutics has not reported any payouts.
  • Unable to verify if BriaCell Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BriaCell Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BriaCell Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BriaCell Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BriaCell Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BriaCell Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BriaCell Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bill Williams
COMPENSATION CA$227,755
TENURE AS CEO 2.5 years
CEO Bio

Dr. William V. Williams, M.D. also known as Bill, has been the Chief Executive Officer and President of BriaCell Therapeutics Corp. since November 1, 2016. Dr. Williams is a seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies. Dr. Williams served as VP of Exploratory Development at Incyte Corporation from 2005 - 2016. There he facilitated entry of over 20 compounds into the clinic, including ruxolitinib (Jakafi), baricitinib, and epacadostat. He was responsible for establishing proof-of-concept in several therapeutic areas, and has been involved in numerous new drug applications (NDAs) for therapeutics that achieved marketing authorization in multiple therapeutic areas including oncology. This includes Jakafi for myelofibrosis and polycythemia vera and baricitinib for rheumatoid arthritis. As Head of Experimental Medicine and VP of Clinical Pharmacology at GlaxoSmithKline, Dr. Williams evaluated several molecules in clinical studies in various therapeutic areas. He ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug development. He supported drug development programs with a wide range of clinical applications. The clinical pharmacology of lapatinib, an orally active drug for breast cancer and other solid tumors, was characterized under his supervision. He was involved in new or supplemental drug authorizations for a number of oncology drugs including Bexxar (lymphoma), Hycamtin (ovarian cancer), and Navelbine (non-small cell lung cancer) as well as ibandronate (Boniva) for osteoporosis. Dr. Williams served as Head of Rheumatology Research at the University of Pennsylvania, ran a major research program in receptor biology, including developing bioactive peptides that mimicked granulocyte-macrophage colony-stimulating factor (GM-CSF), a known stimulant of the immune system. He collaborated with David B. Weiner, Ph.D., a well-known leader in immuno-oncology and vaccine research, in the development of DNA vaccines and was able to bring novel DNA vaccines into the clinic for the treatment of cutaneous T cell lymphoma. Dr. Williams earned his BSc. in Chemistry and Biotechnology from Massachusetts Institute of Technology in the year 1972 to 1976 and Medical Doctorate from Tufts University School of Medicine in the year 1976 to 1980. Following his residency at the Boston VA Medical Center, Dr. Williams completed fellowship training in Rheumatology and Cellular Immunology at the University of Missouri. He then joined the molecular immunology laboratory of Mark I. Greene, MD, PhD, FRCP, at the University of Pennsylvania, developed novel methods of bioactive peptide design, and collaborated in the study of the activation of the p185/Human epidermal growth factor receptor 2 (HER2) receptor. HER-2 is a protein which is known to promote the growth of cancer cells. Dr. Williams is the named author at over 130 peer reviewed publications, over 15 patents and numerous Investigational New Drugs (INDs) and NDAs.

CEO Compensation
  • Bill's compensation has been consistent with company performance over the past year.
  • Bill's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the BriaCell Therapeutics management team in years:

3.3
Average Tenure
  • The tenure for the BriaCell Therapeutics management team is about average.
Management Team

Bill Williams

TITLE
CEO, President & Director
COMPENSATION
CA$228K
TENURE
2.5 yrs

Charles Wiseman

TITLE
Founder & Director
COMPENSATION
CA$84K
TENURE
3.9 yrs

Gadi Levin

TITLE
CFO & Corporate Secretary
COMPENSATION
CA$56K
AGE
45
TENURE
3.3 yrs

Farrah Dean

TITLE
Manager of Corporate Development
Board of Directors Tenure

Average tenure and age of the BriaCell Therapeutics board of directors in years:

2
Average Tenure
66
Average Age
  • The average tenure for the BriaCell Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jamieson Bondarenko

TITLE
Chairman of the Board
COMPENSATION
CA$3K
TENURE
0.2 yrs

Bill Williams

TITLE
CEO, President & Director
COMPENSATION
CA$228K
TENURE
2.5 yrs

Charles Wiseman

TITLE
Founder & Director
COMPENSATION
CA$84K
TENURE
4.5 yrs

Vaughn Embro-Pantalony

TITLE
Director
TENURE
1.2 yrs

Douglas Faller

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs

Thomas Kieber-Emmons

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs

Brian Metcalf

TITLE
Member of Scientific Advisory Board
AGE
72
TENURE
2 yrs

Maria Trojanowska

TITLE
Member of Scientific Advisory Board
TENURE
2 yrs

Bob Williams

TITLE
Member of Scientific Advisory Board
AGE
63
TENURE
2 yrs

Becky Taub

TITLE
Director
AGE
66
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by BriaCell Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
25. Mar 19 Buy Jamieson Bondarenko Individual 25. Mar 19 25. Mar 19 5,000,000 CA$0.10 CA$499,997
12. Apr 19 Buy Jamieson Bondarenko Individual 12. Apr 19 12. Apr 19 250,000 CA$0.11 CA$27,500
14. Jun 18 Buy KJN Management Ltd Company 13. Jun 18 14. Jun 18 100,000 CA$0.15 CA$14,563
X
Management checks
We assess BriaCell Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BriaCell Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Type Of Shareholder Owns BriaCell Therapeutics Corp.'s (CVE:BCT)?

BriaCell Therapeutics is a smaller company with a market capitalization of CA$13m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that. … Check out our latest analysis for BriaCell Therapeutics

Simply Wall St -

Who Really Owns BriaCell Therapeutics Corp (CVE:BCT)?

In this article, I will take a quick look at BriaCell Therapeutics Corp’s (CVE:BCT) recent ownership structure – an unconventional investing subject, but an important one. … The impact of a company's ownership structure affects both its short- and long-term performance. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

What Kind Of Risk Should You Expect For BriaCell Therapeutics Corp (CVE:BCT)?

A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … With a beta of 2.55, BriaCell Therapeutics is a stock that tends to experience more gains than the market during a growth phase and also a bigger reduction in value compared to the market during a broad downturn. … BCT, with its market capitalisation of CA$12.93M, is a small-cap stock, which generally have higher beta than similar companies of larger size.

Simply Wall St -

Why BriaCell Therapeutics Corp's (CVE:BCT) Investor Composition Impacts Your Returns

Check out our latest analysis for BriaCell Therapeutics TSXV:BCT Ownership_summary Mar 15th 18 Insider Ownership Another important group of shareholders are company insiders. … Insider ownership has to do more with how the company is managed and less to do with the direct impact of the magnitude of shares trading on the market. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors.

Simply Wall St -

TSXV Healthcare Industry: A Deep Dive Into BriaCell Therapeutics Corp (CVE:BCT)

If your initial investment thesis is around the growth prospects of BriaCell Therapeutics, there are other biotech companies that have delivered higher growth, and perhaps trading at a discount to the industry average. … Although its growth has delivered lower growth relative to its biotech peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation. … Before you make a decision on the stock, I suggest you look at BriaCell Therapeutics’s future cash flows in order to assess whether the stock is trading at a reasonable price.

Simply Wall St -

How Should You Think About BriaCell Therapeutics Corp's (CVE:BCT) Risks?

A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … How BCT's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive. … Thus, we can expect BCT to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.

Simply Wall St -

Why BriaCell Therapeutics Corp's (TSXV:BCT) Ownership Structure Is Important

Today, I will be analyzing BriaCell Therapeutics Corp’s (TSXV:BCT) recent ownership structure, an important but not-so-popular subject among individual investors. … View our latest analysis for BriaCell Therapeutics TSXV:BCT Ownership_summary Dec 12th 17 Insider Ownership I find insiders are another important group of stakeholders, who are directly involved in making key decisions related to the use of capital. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors.

Simply Wall St -

Company Info

Description

BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company, develops personalized treatments for cancer. Its lead product candidate is Bria-IMT, a clinical trial in combination with pembrolizumab (KEYTRUDA; manufactured by Merck & Co., Inc.) for use in patients with breast cancer. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer patients; and BriaDX, its companion diagnostic test. Its preclinical small molecule program consists of protein kinase C delta inhibitors for cancer and fibrotic diseases. BriaCell Therapeutics Corp. has a clinical trial collaboration and supply agreement with Incyte Corporation for developing Bria-IMT with compounds for treating breast cancer. The company is headquartered in West Vancouver, Canada.

Details
Name: BriaCell Therapeutics Corp.
BCT
Exchange: TSXV
Founded:
CA$16,755,918
197,128,450
Website: http://www.briacell.com
Address: BriaCell Therapeutics Corp.
Bellevue Centre,
Suite 300,
West Vancouver,
British Columbia, V7T 2X1,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV BCT Common Shares TSX Venture Exchange CA CAD 28. Nov 2014
OTCPK BCTX.F Common Shares Pink Sheets LLC US USD 28. Nov 2014
DB 8BT Common Shares Deutsche Boerse AG DE EUR 28. Nov 2014
Number of employees
Current staff
Staff numbers
0
BriaCell Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 02:05
End of day share price update: 2019/05/17 00:00
Last earnings filing: 2019/03/28
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.